From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease: Out with the Old, in with the New
Open accessAbstract
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) affecting a quarter of the global population [...]
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The vast majority of patients with confirmed NAFLD meet the criteria for MASLD, so historical NAFLD/NASH data remain relevant overall.
“According to recent reviews, the vast majority of patients with confirmed NAFLD meet the criteria for MASLD [34,35,36], so historical data remain relevant overall.”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781 · see citing works
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472 · see citing works
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286 · see citing works
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903 · see citing works
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101133 · Cited by 844 · see citing works
Noureddin, M., Vipani, A., Bresee, C. J., Todo, T., Kim, I. K., Alkhouri, N., Setiawan, V. W., Tran, T. T., Ayoub, W. S., Lu, S. C.-L., et al. (2018) · The American Journal of Gastroenterology · doi:10.1038/s41395-018-0088-6 · Cited by 578 · see citing works
Self-citationCan we use old NAFLD data under the new MASLD definition?
Song, S. J., Lai, J. C.-T., Wong, G. L.-H., Wong, V. W.-S., & Yip, T. C.-F. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.021 · Cited by 374 · see citing works
Non-alcoholic fatty liver disease: Definition and subtypes
Han, S. K., Baik, S. K., & Kim, M. Y. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0424 · Cited by 263 · see citing works
Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world
Henry, L. L., Paik, J. M., & Younossi, Z. M. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17158 · Cited by 217 · see citing works
Nonalcoholic fatty liver disease
Schaffner, F., & Thaler, H. (2020) · Nursing · doi:10.1097/01.nurse.0000656496.00204.01 · Cited by 180 · see citing works
Clinical Trial Landscape in NASH
Harrison, S. A., Loomba, R. S., Dubourg, J., Ratziu, V., & Noureddin, M. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.03.041 · Cited by 140 · see citing works
Self-citationHardy, T., Wonders, K., Younes, R., Aithal, G. P., Aller, R., Allison, M., Bédossa, P., Betsou, F., Boursier, J., Brosnan, M. J., et al. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.106175 · Cited by 138 · see citing works
Kim, G., Moon, J. H., & Kim, W. K. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0277 · Cited by 122 · see citing works
Alqahtani, S. A., Chan, W., & Yu, M. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.019 · Cited by 32 · see citing works
“Dual aetiology fatty liver disease”: A recently proposed term associated with potential pitfalls
Moreno, C., Sheron, N., TINIAKOS, D. G., Lackner, C., & Mathurin, P. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.004 · Cited by 23 · see citing works
Yeh, M., & Yu, M. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0359 · Cited by 23 · see citing works
Potential Therapeutic Targets and Promising Agents for Combating NAFLD
Umemura, A., Kataoka, S., Okuda, K., Seko, Y., Yamaguchi, K., Moriguchi, M., Okanoue, T., & Itoh, Y. (2022) · Biomedicines · doi:10.3390/biomedicines10040901 · Cited by 15 · see citing works
Non‐Alcoholic Fatty Liver Disease
Day, C. (2004) · doi:10.1002/9780470987025.ch26 · Cited by 12 · see citing works
Carr, R. M. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000275 · Cited by 1 · see citing works
Flagged first, then by citations
1 of the 20 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches
Radosavljević, T. S., Branković, M., Samardžić, J., Djuretić, J., Vukićević, D., Vučević, D. B., & Jakovljevic, V. L. (2024) · Antioxidants · doi:10.3390/antiox13080906 · Cited by 76 · see citing works
Ahmed, M., & Ahmed, M. H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133893 · Cited by 11 · see citing works
The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease
Kotlyarova, A., Iskrina, A., & Kotlyarov, S. (2026) · International journal of molecular sciences · doi:10.3390/ijms27083399 · Cited by 5 · see citing works
Абатуров, А. Е., & Нікуліна, А. О. (2024) · CHILD`S HEALTH · doi:10.22141/2224-0551.19.2.2024.1683 · Cited by 3 · see citing works
Uzyanbaev, I. A., Timoshenko, S., Спирина, Л. В., & Матвеева, М. В. (2026) · Current Drug Targets · doi:10.2174/0113894501398066251211070417
- Authors
- Alabdul Razzak, I., Noureddin, M., & Trivedi, H.
- Affiliations
- Department of Medicine, St. Elizabeth’s Medical Center, Tufts School of Medicine, Boston, MA 02111, USA
- Houston Methodist (US)
- Cedars-Sinai Medical Center (US)
- Corresponding author
- Trivedi, Hirsh
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2024-02-02
- Volume
- 13
- Issue
- 3
- Pages
- 880
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC10856125
- OpenAlex
- W4391486426
- Cited by
- 5
- References
- 20
- Citations by year
- 2026: 2 · 2024: 3
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, chronic liver disease, disease nomenclature, disease classification
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
